IVVAC-3S/P1
Status:Completed
Phase:I/II
Principal Investigator(s):Christine Katlama, MD Assistance Publique - Hôpitaux de Paris
Objective:The purpose of this trial is to evaluate the safety and immunogenicity of the therapeutic vaccine candidate VAC-3S in HIV-1 infected patients under AntiRetroviral Therapy (ART) with undetectable viral loads.
Prevention Option(s):Therapeutic Vaccines
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionLow dose:
VAC-3S: Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL 3 vaccinations at one month apart
Mode of Delivery
ARMsExperimental
DescriptionMedium dose:
VAC-3S: Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL 3 vaccinations at one month apart
Mode of Delivery
ARMsExperimental
DescriptionHigh dose:
VAC-3S: Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL 3 vaccinations at one month apart
Mode of Delivery
ARMsExperimental
Official Code:
NCT01549119
Trial Sponsors:
InnaVirVax
Start Date
End Date
February 29, 2012
December 31, 2013
Enrollment:24
Age range:
18 Years ↔
55 Years
Population:Cisgender Men, Cisgender Women, People Living with HIV